Twist Bioscience (TWST) EBT (2017 - 2026)

Twist Bioscience (TWST) has reported EBT for 10 consecutive years, with -$34.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 268.8% year-over-year to -$34.7 million in Q2 2026; TTM through Jun 2026 was -$135.9 million, a 60.17% decrease from a year earlier, with the FY2025 full-year figure at -$77.0 million, up 63.03% from the prior year.
• EBT was -$34.7 million for Q2 2026 at Twist Bioscience, up from -$44.0 million in the prior quarter.
• Over five years, EBT peaked at $20.6 million in Q2 2025 and troughed at -$85.4 million in Q2 2024.
• A 5-year average of -$42.8 million and a median of -$43.4 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT surged 124.11% in 2025 and tumbled 268.8% in 2026, its largest moves.
• Over 5 years, EBT stood at -$41.7 million in 2022, then decreased by 2.73% to -$42.9 million in 2023, then increased by 26.56% to -$31.5 million in 2024, then rose by 3.95% to -$30.3 million in 2025, then declined by 14.83% to -$34.7 million in 2026.
• The last three EBT figures came in at -$34.7 million (Q2 2026), -$44.0 million (Q1 2026), and -$30.3 million (Q4 2025), per Business Quant data.